Article at a Glance

Celltrion is expected to achieve annual sales of 1 trillion KRW with its 토토사이트 토스 입금similar ‘Remsima’ as a single product, while key companies such as Alteogen, Orum Therapeutics, and LegoChem 토토사이트 토스 입금sciences are promoting the capabilities of K-토토사이트 토스 입금 on the global stage through technology exports and collaborations with global pharmaceutical companies. Additionally, Yuhan Corporation has once again demonstrated K-토토사이트 토스 입금’s technological prowess in the global market with the U.S. FDA approval of its anticancer drug LECLAZA. In particular, K-토토사이트 토스 입금 is strategically maximizing treatment efficacy through combination therapies with innovative drugs from major pharmaceutical companies or by leveraging cutting-edge platform technologies to create a strong market presence rather than competing directly with global big pharma. However, for K-토토사이트 토스 입금 to sustain its growth, additional investment and support for global expansion are essential. Many companies are currently pointing to insufficient research funding and a lack of infrastructure to navigate global regulatory requirements as major obstacles, and to overcome these challenges, proactive government policies, regulatory easing, and large-scale investments are necessary.

---

The year 2024 is expected to be a milestone in the history of K-토토사이트 토스 입금. This is because domestic 토토사이트 토스 입금tech companies, including Yuhan Corporation and Hanmi Phar maceutical Co., have successfully developed new drugs, either makinginroads into the global market or preparing for entry, while 토토사이트 토스 입금tech ventures such as Alteogen have proven K-토토사이트 토스 입금’s technological capabilities by securing large-scale technology export deals. In particular, Celltrion’s 토토사이트 토스 입금similar ‘Remsima’ (a 토토사이트 토스 입금logic drug replicating an existing reference product) is on track to achieve 1 trillion KRW in sales as a single product this year. Analysts predict that producing a blockbuster drug in the United States and Europe— the world’s largest and second-largest pharmaceutical and 토토사이트 토스 입금tech markets—will serve as a catalyst for renewed global recognition of Korea’s pharmaceutical and 토토사이트 토스 입금tech industries. Additionally, the Contract Manufacturing Organization (CMO) sector, led by Samsung 토토사이트 토스 입금logics, one of the world’s top- tier 토토사이트 토스 입금pharmaceutical contract manufacturers, continues to demonstrate its competitiveness.

The rise of K-토토사이트 토스 입금 is closely linked to global trends in the 토토사이트 토스 입금technology market. In 2023, as global liquidity tightened, investor sentiment plummeted, leading many big pharma and 토토사이트 토스 입금tech companies to implement workforcereductions and restructuring measures. However, despite these harsh conditions, the U.S. Food and Drug Administration (FDA) achieved notable results, approving a total of 55 new drugs in 2023 (based on CDER criteria). This marks a nearly 50% increase compared to 37 approvals in 2022, serving as a positive signal for the broader 토토사이트 토스 입금tech industry. In particular, global interest in antibody-drug conjugates (ADC) has continued into 2024. As an essential technology for developing highly advanced and personalized treatments, such as cancer therapies, ADC technology is expected to emerge as a key driver of growth in the 토토사이트 토스 입금pharmaceutical industry.

인기기사